Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. 1990

F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, Italy.

Augmentin (875 amoxicillin and 125 mg potassium clavulanate) was administered orally to patients with chronic bronchitis. Concentrations of amoxicillin and clavulanic acid were measured in serum, sputum and urine. Peak serum levels for amoxicillin of 11.23 +/- 2.61 micrograms/ml were observed at 2 hours and for clavulanic acid of 2.55 +/- 0.54 micrograms/ml at 1 hour. After 9 hours, 50% of the amoxicillin and 39% of the clavulanic acid had been renally excreted. The peak sputum concentration of amoxicillin was 1.31 +/- 0.42 micrograms/ml at 4 hours and of clavulanate was 0.79 +/- 0.23 micrograms/ml at 2 hours. Patients awaiting surgery received an oral dose of augmentin as above. Samples of lung, tonsil, middle ear mucosa and prostate were obtained and tissue concentrations of both compounds measured. Peak levels of amoxicillin ranged from 0.87 micrograms/g (tonsil) to 2.56 micrograms/g (lung) and of clavulanic acid from 0.20 micrograms/g (prostate) to 0.56 micrograms/g (lung) between 3 and 4 hours after dosing.

UI MeSH Term Description Entries
D001991 Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI. Bronchitides
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002969 Clavulanic Acids Acids, salts, and derivatives of clavulanic acid (C8H9O5N). They consist of those beta-lactam compounds that differ from penicillin in having the sulfur of the thiazolidine ring replaced by an oxygen. They have limited antibacterial action, but block bacterial beta-lactamase irreversibly, so that similar antibiotics are not broken down by the bacterial enzymes and therefore can exert their antibacterial effects. Acids, Clavulanic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000658 Amoxicillin A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration. Hydroxyampicillin,Actimoxi,Amoxicillin Anhydrous,Amoxicillin Monopotassium Salt,Amoxicillin Monosodium Salt,Amoxicillin Sodium,Amoxicillin Trihydrate,Amoxicillin, (R*)-Isomer,Amoxicilline,Amoxil,Amoxycillin,BRL-2333,Clamoxyl,Clamoxyl G.A.,Clamoxyl Parenteral,Penamox,Polymox,Trimox,Wymox,BRL 2333,BRL2333
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D015337 Multicenter Studies as Topic Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D019980 Amoxicillin-Potassium Clavulanate Combination A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate. Amoxicillin-Clavulanic Acid,Potassium Clavulanate-Amoxicillin Combination,Amox-clav,Amoxi-Clavulanate,Amoxycillin-Clavulanic Acid,Augmentin,BRL-25000,Clavulanate Potentiated Amoxycillin,Clavulin,Co-amoxiclav,Coamoxiclav,Spektramox,Synulox,Amox clav,Amoxi Clavulanate,Amoxicillin Clavulanic Acid,Amoxicillin Potassium Clavulanate Combination,Amoxycillin Clavulanic Acid,Amoxycillin, Clavulanate Potentiated,BRL 25000,BRL25000,Co amoxiclav,Potassium Clavulanate Amoxicillin Combination

Related Publications

F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
June 2000, The Laryngoscope,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
December 1995, The veterinary quarterly,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
September 2019, Journal of veterinary pharmacology and therapeutics,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
October 1984, Journal of clinical pharmacology,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
December 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
January 1998, Research in veterinary science,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
January 2021, Journal of veterinary pharmacology and therapeutics,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
January 2004, Therapie,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
April 1995, Journal of veterinary pharmacology and therapeutics,
F Fraschini, and F Scaglione, and M Falchi, and S Dugnani, and M Mezzetti, and F Cicchetti, and G Alfano, and G P Pintucci
December 1995, Avian pathology : journal of the W.V.P.A,
Copied contents to your clipboard!